Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS).
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 24029743.
- Also identified by DOI 10.1136/thoraxjnl-2013-203897 and PMC identifier 3954445.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.
Medical subject headings
- Biomarkers
- Disease Management
- Pulmonary Disease, Chronic Obstructive